Compare Medpace Holdings Inc (MEDP) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance

MEDP trades at $609.89, down 1.64% today, with a bullish technical signal and strong support near $606. The company reported robust earnings beats in recent quarters, with Q2 2026 EPS of $4.25 beating expectations of $3.98. Revenue grew to $2.53B in 2025, with a net income margin of 17.67%. Recent news highlights CEO stock sales and institutional position adjustments.

Outlook remains positive with a consensus price target of $620.44, offering modest upside. Key risks include high valuation multiples and insider selling. Earnings growth and sector demand are primary catalysts, but investor caution is warranted given elevated P/E and P/B ratios.

Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.

The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.